Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

1.

A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.

Uboldi S, Calura E, Beltrame L, Fuso Nerini I, Marchini S, Cavalieri D, Erba E, Chiorino G, Ostano P, D'Angelo D, D'Incalci M, Romualdi C.

PLoS One. 2012;7(4):e35423. doi: 10.1371/journal.pone.0035423. Epub 2012 Apr 16.

PMID:
22523595
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.

Uboldi S, Bernasconi S, Romano M, Marchini S, Fuso Nerini I, Damia G, Ganzinelli M, Marangon E, Sala F, Clivio L, Chiorino G, Di Giandomenico S, Rocchi M, Capozzi O, Margison GP, Watson AJ, Caccuri AM, Pastore A, Fossati A, Mantovani R, Grosso F, Tercero JC, Erba E, D'Incalci M.

Int J Cancer. 2012 Jul 1;131(1):59-69. doi: 10.1002/ijc.26340. Epub 2011 Aug 30.

PMID:
21805478
[PubMed - indexed for MEDLINE]
3.

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG.

Lancet Oncol. 2007 Jul;8(7):595-602.

PMID:
17586092
[PubMed - indexed for MEDLINE]
4.

Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.

Frapolli R, Tamborini E, Virdis E, Bello E, Tarantino E, Marchini S, Grosso F, Sanfilippo R, Gronchi A, Tercero JC, Peloso G, Casali P, Pilotti S, D'Incalci M.

Clin Cancer Res. 2010 Oct 15;16(20):4958-67. doi: 10.1158/1078-0432.CCR-10-0317. Epub 2010 Aug 20.

PMID:
20732964
[PubMed - indexed for MEDLINE]
Free Article
5.

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D'Incalci M, Pilotti S, Mantovani R.

Mol Cancer Ther. 2009 Feb;8(2):449-57. doi: 10.1158/1535-7163.MCT-08-0848. Epub 2009 Feb 3.

PMID:
19190116
[PubMed - indexed for MEDLINE]
Free Article
6.

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P.

Cancer Res. 2010 Mar 15;70(6):2235-44. doi: 10.1158/0008-5472.CAN-09-2335. Epub 2010 Mar 9.

PMID:
20215499
[PubMed - indexed for MEDLINE]
Free Article
7.

The intriguing patterns of tumor response to trabectedin.

Sanfilippo R, Casali PG.

Expert Rev Anticancer Ther. 2013 Jun;13(6 Suppl 1):21-4. doi: 10.1586/era.13.51.

PMID:
23638727
[PubMed - indexed for MEDLINE]
8.

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.

D'Incalci M, Badri N, Galmarini CM, Allavena P.

Br J Cancer. 2014 Aug 12;111(4):646-50. doi: 10.1038/bjc.2014.149. Epub 2014 Apr 22. Review.

PMID:
24755886
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Trabectedin--a targeted chemotherapy?

von Mehren M.

Lancet Oncol. 2007 Jul;8(7):565-7. No abstract available.

PMID:
17613417
[PubMed - indexed for MEDLINE]
10.

Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.

Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ.

Neoplasia. 2011 Feb;13(2):145-53.

PMID:
21403840
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.

Dossi R, Frapolli R, Di Giandomenico S, Paracchini L, Bozzi F, Brich S, Castiglioni V, Borsotti P, Belotti D, Uboldi S, Sanfilippo R, Erba E, Giavazzi R, Marchini S, Pilotti S, D'Incalci M, Taraboletti G.

Int J Cancer. 2015 Feb 1;136(3):721-9. doi: 10.1002/ijc.29023. Epub 2014 Jun 19.

PMID:
24917554
[PubMed - indexed for MEDLINE]
12.

Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.

García MJ, Saucedo-Cuevas LP, Muñoz-Repeto I, Fernández V, Robles MJ, Domingo S, Palacios J, Aracil M, Nieto A, Tercero JC, Benítez J.

Mol Cancer Ther. 2013 Apr;12(4):530-41. doi: 10.1158/1535-7163.MCT-12-0768. Epub 2013 Jan 30.

PMID:
23364677
[PubMed - indexed for MEDLINE]
Free Article
13.

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.

Gronchi A, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, Hohl RJ, Demetri GD, Le Cesne A, Lardelli P, Pérez I, Nieto A, Tercero JC, Alfaro V, Tamborini E, Blay JY.

Ann Oncol. 2012 Mar;23(3):771-6. doi: 10.1093/annonc/mdr265. Epub 2011 Jun 3.

PMID:
21642514
[PubMed - indexed for MEDLINE]
Free Article
14.

Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma.

Kuroda M, Ishida T, Horiuchi H, Kida N, Uozaki H, Takeuchi H, Tsuji K, Imamura T, Mori S, Machinami R, et al.

Am J Pathol. 1995 Nov;147(5):1221-7.

PMID:
7485386
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Trabectedin therapy for sarcomas.

Casali PG, Sanfilippo R, D'Incalci M.

Curr Opin Oncol. 2010 Jul;22(4):342-6. doi: 10.1097/CCO.0b013e32833aaac1. Review.

PMID:
20489618
[PubMed - indexed for MEDLINE]
16.

Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.

[No authors listed]

Drugs R D. 2006;7(5):317-28. Review.

PMID:
16922593
[PubMed - indexed for MEDLINE]
17.

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.

Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, Casali PG, Balaña C, Schöffski P, Grosso F, Lardelli P, Nieto A, Alfaro V, Demetri GD.

Eur J Cancer. 2012 Nov;48(16):3036-44. doi: 10.1016/j.ejca.2012.05.012. Epub 2012 Jun 29.

PMID:
22749255
[PubMed - indexed for MEDLINE]
18.

Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.

Martínez N, Sánchez-Beato M, Carnero A, Moneo V, Tercero JC, Fernández I, Navarrete M, Jimeno J, Piris MA.

Mol Cancer Ther. 2005 May;4(5):814-23.

PMID:
15897246
[PubMed - indexed for MEDLINE]
Free Article
19.

Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues.

Hisaoka M, Tsuji S, Morimitsu Y, Hashimoto H, Shimajiri S, Komiya S, Ushijima M.

Diagn Mol Pathol. 1998 Apr;7(2):96-101.

PMID:
9785008
[PubMed - indexed for MEDLINE]
20.

Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.

Marchini S, Marrazzo E, Bonomi R, Chiorino G, Zaffaroni M, Weissbach L, Hornicek FJ, Broggini M, Faircloth GT, D'Incalci M.

Eur J Cancer. 2005 Jan;41(2):323-33.

PMID:
15661559
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk